Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

Benzinga Newsdesk www.benzinga.com Positive 81.7%

Neg 0% Neu 0% Pos 81.7%

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.